1. Home
  2. AVDL vs MEGI Comparison

AVDL vs MEGI Comparison

Compare AVDL & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • MEGI
  • Stock Information
  • Founded
  • AVDL 2015
  • MEGI 2021
  • Country
  • AVDL Ireland
  • MEGI United States
  • Employees
  • AVDL N/A
  • MEGI N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • MEGI Investment Managers
  • Sector
  • AVDL Health Care
  • MEGI Finance
  • Exchange
  • AVDL Nasdaq
  • MEGI Nasdaq
  • Market Cap
  • AVDL 784.6M
  • MEGI 689.1M
  • IPO Year
  • AVDL 1996
  • MEGI N/A
  • Fundamental
  • Price
  • AVDL $9.46
  • MEGI $13.65
  • Analyst Decision
  • AVDL Strong Buy
  • MEGI
  • Analyst Count
  • AVDL 7
  • MEGI 0
  • Target Price
  • AVDL $18.86
  • MEGI N/A
  • AVG Volume (30 Days)
  • AVDL 1.2M
  • MEGI 178.0K
  • Earning Date
  • AVDL 05-07-2025
  • MEGI 01-01-0001
  • Dividend Yield
  • AVDL N/A
  • MEGI 11.40%
  • EPS Growth
  • AVDL N/A
  • MEGI N/A
  • EPS
  • AVDL N/A
  • MEGI N/A
  • Revenue
  • AVDL $194,450,000.00
  • MEGI N/A
  • Revenue This Year
  • AVDL $50.53
  • MEGI N/A
  • Revenue Next Year
  • AVDL $32.33
  • MEGI N/A
  • P/E Ratio
  • AVDL N/A
  • MEGI N/A
  • Revenue Growth
  • AVDL 252.64
  • MEGI N/A
  • 52 Week Low
  • AVDL $6.38
  • MEGI $10.63
  • 52 Week High
  • AVDL $17.85
  • MEGI $14.89
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 65.93
  • MEGI 62.09
  • Support Level
  • AVDL $8.55
  • MEGI $13.32
  • Resistance Level
  • AVDL $9.98
  • MEGI $13.70
  • Average True Range (ATR)
  • AVDL 0.50
  • MEGI 0.22
  • MACD
  • AVDL 0.11
  • MEGI 0.05
  • Stochastic Oscillator
  • AVDL 77.73
  • MEGI 87.28

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund

MainStay CBRE Global Infrastructure Megatrends Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It invests predominantly in income-producing equity securities issued by infrastructure companies, including common stock, preferred stock, convertible securities, and rights or warrants to buy common stocks. The company intends to focus on three infrastructure megatrends: decarbonization, digital transformation, and asset modernization while making its investments.

Share on Social Networks: